New drug shows promise in shrinking lung tumors before surgery
NCT ID NCT05740943
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests whether the targeted drug lorlatinib can shrink tumors in people with stage III non-small cell lung cancer that has a specific gene change (ALK fusion). About 48 adults will take lorlatinib before possibly having surgery. The main goal is to see if the cancer completely disappears in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Guangzhou Twelfth People's Hospital
Guangzhou, Guangdong, China
-
Peking Union Medical College Hospital
Beijin, Beijin, 100730, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
Conditions
Explore the condition pages connected to this study.